Medi-Tate is a medical device manufacturer engaged in the research and development, production, and sale of devices for the treatment of Benign Prostatic Hyperplasia (BPH). The company’s product
“iTind” is European CE marked. The intention is to proceed with a progressive rollout of the product by obtaining regulatory approvals and other relevant licenses in select countries.
Olympus intends to leverage Medi-Tate’s technology to further expand its range of Minimally Invasive Surgical Treatment (MIST) devices for BPH and to strengthen its urology business.
The Medi-Tate investment will allow Olympus to strengthen its support in Urology through expanded options in enhanced patient care, with complementary offerings to its already robust BPH product
portfolio. The existing resection and vaporization portfolio will continue to be fully supported by Olympus.